Insulin controls hyperglycemia caused by diabetes,and virtually all treatments require exogenous insulin. The monomeric B27 Lys destripeptide insulin has 80% bioactivity of wild type. It is a potential drug for clinic...Insulin controls hyperglycemia caused by diabetes,and virtually all treatments require exogenous insulin. The monomeric B27 Lys destripeptide insulin has 80% bioactivity of wild type. It is a potential drug for clinic. But the yield of monomeric B27 Lys destripeptide insulin is limited, because monomeric B27 Lys destripeptide insulin precursor( MIP) was easily to form inclusion body,when MIP is expressed in E. coli. The precursor,MIP,is not only fused to an N-terminal HIS-small ubiquitin-related modifier( SUMO) tag,but also added five Arginine( 5 R) at the C-terminal,which can improve the solubility of the fusion protein. By this way,the yield of fusion protein has been up to 1. 45 mg/L cell culture.This work set up the foundation for the clinical application of B27 Lys destripeptide insulin.展开更多
Antifungal activity of recombinant medicinal leech destabilase-lysozyme （rec.Dest-Lys） was investi- gated by using fungi： Botrytis cinerea, and Verticillium lateriticum, including yeasts Candida guillermoudii and S...Antifungal activity of recombinant medicinal leech destabilase-lysozyme （rec.Dest-Lys） was investi- gated by using fungi： Botrytis cinerea, and Verticillium lateriticum, including yeasts Candida guillermoudii and Shizosaccharomyces pombe. Its antibacterial activity was investigated on gram-negative bacteria Pseudomonas fluorescens. These activities were assessed by radial agar diffusion assay, and scanning and transmission electron microscopy. Therefore, destabilase-lysozyme not only is endo-isopeptidase and lysozyme, but also has antifungal and antibacterial activities. Muramidase activity of rec. Dest-Eys disappeared after heat-treating at 90~C for 50 min without the loss of its antimicrobial activity. Furthermore we showed for the first time that the heated-up derivative ofrec.Dest-Lys exhibited more potent activities against the above enumerated fungi and gram-negative bacteria than original protein.展开更多
基金China Postdoctoral Science Foundation Projects(No.2015M571455)National Undergraduate Training Program for Innovation and Entrepreneurship,China(No.17T10509)
文摘Insulin controls hyperglycemia caused by diabetes,and virtually all treatments require exogenous insulin. The monomeric B27 Lys destripeptide insulin has 80% bioactivity of wild type. It is a potential drug for clinic. But the yield of monomeric B27 Lys destripeptide insulin is limited, because monomeric B27 Lys destripeptide insulin precursor( MIP) was easily to form inclusion body,when MIP is expressed in E. coli. The precursor,MIP,is not only fused to an N-terminal HIS-small ubiquitin-related modifier( SUMO) tag,but also added five Arginine( 5 R) at the C-terminal,which can improve the solubility of the fusion protein. By this way,the yield of fusion protein has been up to 1. 45 mg/L cell culture.This work set up the foundation for the clinical application of B27 Lys destripeptide insulin.
文摘Antifungal activity of recombinant medicinal leech destabilase-lysozyme （rec.Dest-Lys） was investi- gated by using fungi： Botrytis cinerea, and Verticillium lateriticum, including yeasts Candida guillermoudii and Shizosaccharomyces pombe. Its antibacterial activity was investigated on gram-negative bacteria Pseudomonas fluorescens. These activities were assessed by radial agar diffusion assay, and scanning and transmission electron microscopy. Therefore, destabilase-lysozyme not only is endo-isopeptidase and lysozyme, but also has antifungal and antibacterial activities. Muramidase activity of rec. Dest-Eys disappeared after heat-treating at 90~C for 50 min without the loss of its antimicrobial activity. Furthermore we showed for the first time that the heated-up derivative ofrec.Dest-Lys exhibited more potent activities against the above enumerated fungi and gram-negative bacteria than original protein.
